TNFRSF8 and lymphoma: The CD30-specific mAbs Ki-1, Ki-2, Ki-3, Ki-4, Ber-H2, 5F11 (also known as MDX-060 and iratumumab), and AC10 have all been developed as therapeutics for lymphoma.